Pfenex is developing a broad pipeline of biosimilar therapeutics and novel vaccines to provide safe and cost-effective treatments for critical human health issues.
Through the Pfēnex Expression Technology™ platform, Pfenex possesses the unprecedented ability to rapidly and reproducibly produce proteins that cannot be otherwise expressed in any other system. With advantages including quality, stability, solubility, and titer Pfenex reduces production and development costs enabling the rapid delivery of products through the clinic and into commercialization.
Pfenex is leveraging its cutting edge technology platform for its own product pipeline, strain engineering services for those companies developing therapeutics and vaccines and for those researchers seeking reagents for research use.
Transcending the Limits of Protein Production
Protein expression is difficult… the ability to successfully produce high titers of soluble, active protein in the first attempt results in significant opportunity cost avoidance and rapid product development. Pfenex produces high titers of proteins across a broad spectrum of functional types, from enzymes to antigens and engineered antibody fragments, rapidly and reliably.
The high throughput, combinatorial screening approach of the Pfēnex Expression Technology™, allows Pfenex the unprecedented ability to produce proteins that cannot be otherwise expressed in any other system. Advantages include quality, stability, solubility, titer, rapid delivery as well as reduced production and development costs.